px 478
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00522652)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hypoxia-inducible factor 1-alphaINHIBITOR
HIF1A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-amino-3-(4'-n,n-bis(2-chloroethyl)amino)phenylpropionic acid n-oxide
- px 478
- px-478
- px-478
- px-478
- px478 cpd
- s-2-amino-3-(4'-n,n-bis(2-chloroethyl)amino)phenylpropionic acid n-oxide dihydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00522652 | Phase 1 | Aug 1, 2007 | Cascadian Therapeutics Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cascadian Therapeutics Inc. | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1